Xeris Biopharma Holdings, Inc./$XERS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Ticker
$XERS
Sector
Health
Primary listing
Employees
394
Headquarters
Website
XERS Metrics
BasicAdvanced
$1.1B
-
-$0.21
-
-
Price and volume
Market cap
$1.1B
52-week high
$7.09
52-week low
$3.59
Average daily volume
2.4M
Financial strength
Current ratio
1.95
Quick ratio
1.18
Long term debt to equity
-1,300.596
Total debt to equity
-1,332.485
Interest coverage (TTM)
-0.12%
Profitability
EBITDA (TTM)
8.37
Gross margin (TTM)
82.24%
Net profit margin (TTM)
-13.01%
Operating margin (TTM)
-1.51%
Effective tax rate (TTM)
9.41%
Revenue per employee (TTM)
$620,000
Management effectiveness
Return on assets (TTM)
-0.70%
Return on equity (TTM)
165.84%
Valuation
Price to revenue (TTM)
4.093
Price to book
-54.52
Price to tangible book (TTM)
-7.76
Growth
Revenue change (TTM)
35.62%
Earnings per share change (TTM)
-50.27%
3-year revenue growth (CAGR)
45.50%
3-year earnings per share growth (CAGR)
-43.95%
Bulls say / Bears say
Xeris Biopharma reported a 48% year-over-year increase in total revenue for Q1 2025, reaching over $60 million, with Recorlev® revenue growing 141% year-over-year. (Xeris Biopharma Press Release)
The company announced the approval of a supplemental New Drug Application for Gvoke VialDx™, a ready-to-dilute liquid glucagon, expected to be available in Q3 2025. (Xeris Biopharma Press Release)
Analyst firms have raised their price targets for Xeris Biopharma, with Craig Hallum increasing its target from $5.00 to $6.50 and maintaining a 'buy' rating. (MarketBeat)
Insider selling activity was noted, with insider Beth Hecht selling 40,000 shares in March 2025, potentially signaling concerns about future performance. (MarketBeat)
Keveyis® revenue declined by 23% to $12.2 million in Q3 2024, indicating potential challenges in that product segment. (StockTitan)
Piper Sandler downgraded Xeris Biopharma from an 'overweight' to a 'neutral' rating, setting a $3.00 price objective, reflecting cautious sentiment. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
XERS News
AllArticlesVideos
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
Business Wire·3 days ago
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
Business Wire·1 week ago
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xeris Biopharma Holdings, Inc. stock?
Xeris Biopharma Holdings, Inc. (XERS) has a market cap of $1.1B as of August 10, 2025.
What is the P/E ratio for Xeris Biopharma Holdings, Inc. stock?
The price to earnings (P/E) ratio for Xeris Biopharma Holdings, Inc. (XERS) stock is 0 as of August 10, 2025.
Does Xeris Biopharma Holdings, Inc. stock pay dividends?
No, Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders as of August 10, 2025.
When is the next Xeris Biopharma Holdings, Inc. dividend payment date?
Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders.
What is the beta indicator for Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. (XERS) does not currently have a Beta indicator.